Canos

The cancer screening part of Canos Origin, as a focused test. Cell-free DNA analysis and a cancer screening report. $199 introductory offer, regularly $299.

This page presents veterinary evidence for liquid biopsy in canine cancer detection and monitoring, including RCVS Knowledge and clinical studies.

The page describes Canos’ transition from human cancer care to canine cancer detection, monitoring, and bioinformatics, with clinical guidance and studies.

Methylation-based cancer monitoring for dogs. Track treatment response, minimal residual disease (MRD) and relapse with cell-free DNA analysis. Now $299, reduced from $499.

The page explains routine bloodwork, liquid biopsy, and key questions to consider before selecting a cancer-related test for dogs.

Explore how Canos Origin brings cancer detection, genetics, epigenetics and cfDNA together in a comprehensive genomic health baseline.

This guide covers follow-up care, remission, and the role of molecular residual disease monitoring in a dog’s veterinary care.

The page introduces Canos founders and advisors in veterinary oncology, aging science, and biotechnology intellectual property.

Canos Origin provides genetics, biological age, and cancer screening for dogs, including cell-free DNA analysis and a genomic health baseline.

Human-grade cancer care for dogs. Origin combines cancer detection with a genomic health baseline. OncoTrack follows treatment response and MRD. Blood draws are open.

How Canos collects, uses and protects personal data across the UK and US, including registration, veterinary and genomic sample information.

The terms that govern use of the Canos website, registration and canine blood-testing services in the UK and US.